IR & Research Intelligence, Sessa Investment Research

Sessa Investment Research

IR & Research Intelligence

Sponsored research focusing on Japanese small cap.

Equity Bottom-Up

D.Western Therapeutics Institute Inc. / Equity Bottom-Up

<div><div><div><div><ul><li>DWTI announced that it has updated its development pipeline on DW-1002 licensee Dutch Ophthalmic Research Center (DORC) announcing its decision to develop MEMBRANEBLUE-DUAL® in the US for the indication of ILM and ERM membrane staining during vitreoretinal surgery.</li><li>Since the DW-1002 single-agent formulation TissueBlueTM was launched in the US in 2020, it has been used in over 100,000 surgeries and is preferred by over 40% of U.S. retinal surgeons.</li><li>Combination ophthalmic surgical aid MEMBRANE BLUE-DUAL® (DW-1002 Brilliant Blue G + Trypan Blue) has been used in over 500,000 surgeries in Europe since its launch in 2010. </li></ul></div></div></div></div>

DWTI announced that it has updated its development pipeline on DW-1002 licensee Dutch Ophthalmic Research Center (DORC) announcing its decision to develop MEMBRANEBLUE-DUAL® in the US for the indication of ILM and ERM membrane staining during vitreoretinal surgery.Since the DW-1002 single-agent formulation TissueBlueTM was launched in the US in 2020, it has been used in over 100,000 surgeries and is preferred by over 40% of U.S. retinal surgeons.Combination ophthalmic surgical aid MEMBRANE BLUE-DUAL® (DW-1002 Brilliant Blue G + Trypan Blue) has been used in over 500,000 surgeries in Europe since its launch in 2010. 

News Flash - D. Western Therapeutics Institute (4576 JP)

<ul><li>DWTI announced that out-license partner Dutch Ophthalmic Research Center (International) B.V. (DORC) has submitted a new drug application for approval of DW1002 to the National Medical Products Administration (NMPA) of China for the indication of ILM staining in vitreoretinal surgery (May 30 local time).</li><li>No milestone will be received as a result of this transaction, and there will be no change to the forecast of financial results for the fiscal year ending December 31, 2023.</li><li>DWTI granted an exclusive sublicense for DW-1002 for all regions worldwide outside Japan to DORC, which has been manufacturing and selling the product in Europe and other countries since September 2010.</li></ul>

DWTI announced that out-license partner Dutch Ophthalmic Research Center (International) B.V. (DORC) has submitted a new drug application for approval of DW1002 to the National Medical Products Administration (NMPA) of China for the indication of ILM staining in vitreoretinal surgery (May 30 local time).No milestone will be received as a result of this transaction, and there will be no change to the forecast of financial results for the fiscal year ending December 31, 2023.DWTI granted an exclusive sublicense for DW-1002 for all regions worldwide outside Japan to DORC, which has been manufacturing and selling the product in Europe and other countries since September 2010.

D. Western Therapeutics Institute (4576 JP) - News Flash

<ul><li>According to “Ophthalmology Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030” issued by the Business Research Company in Feb-2021, the global ophthalmology drugs market is expected to grow from $22.03 billion in 2020 to $32.64 billion in 2025 (+8.2% CAGR).</li><li>M&amp;A in this segment has become active in recent years, with global eye care leader Alcon (SIX/NYSE:ALC) acquiring DWTI’s closest rival in the US, Aerie Pharmaceuticals, Inc. in Nov-2022, adding Rhopressa® (similar to DWTI’s GLANATEC®) among others, and Aerie’s development pipeline.</li><li>Over time with progress in execution of the development pipeline, and as part of growth strategy to diversify revenue streams, DWTI’s basic business model of drug discovery and early out-licensing has evolved to include 1) from 2015, in-licensing of later stage development products, 2) from 2018, collaborative drug creation applying DWTI’s technical expertise to assist in joint R&amp;D of products of other firms, and 3) from 2018, extending development of original in-house products beyond early out-licensing as far as proof of concept (PoC) through Phase IIb.</li></ul>

According to “Ophthalmology Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030” issued by the Business Research Company in Feb-2021, the global ophthalmology drugs market is expected to grow from $22.03 billion in 2020 to $32.64 billion in 2025 (+8.2% CAGR).M&amp;A in this segment has become active in recent years, with global eye care leader Alcon (SIX/NYSE:ALC) acquiring DWTI’s closest rival in the US, Aerie Pharmaceuticals, Inc. in Nov-2022, adding Rhopressa® (similar to DWTI’s GLANATEC®) among others, and Aerie’s development pipeline.Over time with progress in execution of the development pipeline, and as part of growth strategy to diversify revenue streams, DWTI’s basic business model of drug discovery and early out-licensing has evolved to include 1) from 2015, in-licensing of later stage development products, 2) from 2018, collaborative drug creation applying DWTI’s technical expertise to assist in joint R&amp;D of products of other firms, and 3) from 2018, extending development of original in-house products beyond early out-licensing as far as proof of concept (PoC) through Phase IIb.

D. Western Therapeutics Institute (DWTI) (4576 JP) - 1Q Follow-Up

Japan

Ribomic, Inc. develops ribonucleic acids (RNA) called aptamers. The company conduct research and develops new medication based on Ribomic Aptamer Refined Th erapeutics System. The company also conduct advisory to pharmaceutical companies and product licensing.

TRANS GENIC INC. develops, produces, and sells specific idiotype bearing antibody (bio reagent).  The Company also develops mutant mice and sells mice' genetic function analysis data.

Gene Techno Science Co., Ltd. is a biomedicine company that researches and developes drugs. In addition to drug development, the company also supply the pharmaceutical ingredients.

AnGes MG, Inc. develops gene-therapy drugs that use Hepatocyte Growth Factor (HGF) for myocardial infarction and arteriosclerosis patients.  The Company also develops nucleic acid drug (decoy oligo) for patients with asthma, allergy, and rheumatism.  AnGes MG develops vectors (a carrier used to introduce a foreign gene into a host cell) which help study and analyze genetic functions.

CanBas Company Ltd. is a biopharmaceutical company that develops anti-cancer drugs with fewer side effects.  The Company's core technologies include drugs that target the G2 checkpoint and a screening system to find selective abrogators of the G2 checkpoint.

Oncolys BioPharma Inc. provides pharmaceutical and diagnostic products and services.. The Company researches, develops, manufactures and sells drugs targeting cancer and serious infectious diseases and also provides inspection services for viruses.

3-D Matrix, Ltd. researches and develops medical products by applying self assembling peptide technology.

OncoTherapy Science Inc., is a biopharmaceutical company. The Company conducts research & development of medicine, treatments, and gene-analysis on cancer.

ReproCell Incorporated develops iPS (Induced Pluripotent Stem Cell) business and clinical examination for organ transplantation based on human iPS and ES (Embryonic Stem Cell) technology.

NanoCarrier Co., Ltd. is a biotech company that utilizes micellar nanoparticle (polymeric micelles) technology for the production and development of pharmaceuticals focusing mainly on cancer therapies.

Calithera Biosciences, Inc. provides pharmaceutical products. The Company is focused on discovering and developing novel small molecule drugs against tumor metabolism and immunology for the treatment of cancer. Calithera Biosciences serves patrients in the United States.

Biotron Limited specializes in the funding, management and commercialization of biomedical projects that result from research conducted at the John Curtin School of Medical Research, a research institute within the Australian National University.  The Group conducts diagnostic and therapeutic research with the intention of creating compounds and diagnostics that can be sold or licensed.

Immuron Limited operates as a biopharmaceutical company. The Company focuses on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron's technology platform is developing and producing an orally stable therapeutic for various immune mediated and inflammatory disorders.

Alterity Therapeutics Limited operates as a biotechnology company. The Company researches and develops therapeutic drugs used for treatment of alzheimer's diseases and age related disorders. Alterity Therapeutics serves patients in Australia.

Aspira Women's Health Inc. operates as a biotech company. The Company develops and discovers testing and treatments for gynecologic issues. Aspira Women's Health serves customers in the State of Texas.

Prescient Therapeutics Limited is an oncology company. The Company researches, develop, and commercializes novel cancer treatments treatments. Prescient Therapeutics treats myeloma, breast, and pancreatic cancer.

Bharat Immunologicals & Biologicals Corporation Ltd. manufactures and distributes pharmaceutical drugs and vaccines. The Company's primary product is oral polio vaccine (OPV).

Vectorite Biotech Inc. is a biomedical company focused on the research and development of adult healthy cells and cell formulation, medical technologies and product development of targeted immune cell therapy treatment to treat disease and improve the patients' quality of life.

Cara Therapeutics, Inc. develops therapeutics. The Company offers novel drugs for the treatment of human diseases associated with pain and inflammation. Cara Therapeutics serves customers in the United States.

Minerva Neurosciences, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops new therapies to treat central nervous system (CNS) and neuropsychiatric diseases. Minerva Neurosciences serves communities in the United States.

D.Western Therapeutics Institute Inc.(DWTI) is a biotechnology (bio-venture) company that focuses on development of new drugs. The Company's focus is on protein kinase inhibitors. DWTI discovers and develops several drugs, such as antiglaucoma, antihypertensive, neuroprotective, antithrombogenic, antiatherosclerosis and anticancer.

D.Western Therapeutics Institute Inc. (4576 JP)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

D.Western Therapeutics Institute Inc. (4576 JP)

News Flash - D. Western Therapeutics Institute (4576 JP)

DW-1002 licensee DORC announces decision to develop MEMBRANEBLUE-DUAL® in the US, received orphan drug designation from the US FDA for expedited...

Sessa Investment Research

D. Western Therapeutics Institute (4576 JP) - News Flash

DWTI announced that out-license partner Dutch Ophthalmic Research Center (International) B.V. (DORC) has submitted a new drug application for...

Sessa Investment Research

D. Western Therapeutics Institute (DWTI) (4576 JP) - 1Q Follow-Up

Development pipeline is steadily expanding FY23/12 initiatives: conducting H-1337 phase IIb trials in the US, DW-1002 approval/launch in China and...

Sessa Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)